Objective:To evaluate the efficacy of dexzopiclone combined with repetitive transcranial magnetic stimulation (rTMS) for post-stroke sleep disorders (PSSD) and its effects on sleep electroencephalography and neuroelectrophysiological parameters.Methods:180 PSSD patients admitted to Yulin First Hospital (December 2019-December 2020) were randomized into medication group ( n=90, dexzopiclone) and rTMS group ( n=90, dexzopiclone+rTMS). Outcomes included clinical efficacy, sleep quality [Pittsburgh Sleep Quality Index (PSQI), Self-Rating Scale for Sleep (SRSS)], electroencephalogram parameters [sleep latency (SL), total sleep time (TST), sleep efficiency], neuroelectrophysiological indices [bilateral motor thresholds], biochemical markers [S100β protein, brain-derived neurotrophic factor (BDNF)], adverse reactions, and 1-year recurrence rate. Results:After treatment, the rTMS group had a significantly higher efficacy (92.22%, 83/90) compared to the medication group (81.11%, 73/90) ( χ2=4.81, P=0.028). Compared to post-treatment, PSQI decreased to [7.47 (6.63,8.69) points vs. 13.56 (3.15,19.51) points] in the rTMS group and [9.56 (8.59,11.11) points vs. 14.01 (2.58,20.55) points] in the medication group ( U=8.82, 8.38; both P<0.001). SRSS scores decreased to [(15.23±2.88) points vs. (28.81±4.99) points) ( t=32.74, P<0.001) and (19.54±3.59) points vs. (28.15±4.71) points) ( t=19.68, P<0.001)], respectively. Compared to before treatment, the rTMS group had lower scores than the medication group ( U=7.80, t=8.88; P<0.01). SL reduced to (27.65±5.12) min vs. (44.92±8.21) min ( t=24.58, P<0.001) in rTMS group and (38.78±6.34) min vs. (45.23±8.56) min ( t=8.24, P<0.001) in medication groups. TST increased to (348.50±56.27) min vs. (299.21±52.14) min ( t=8.63, P<0.001) and (311.42±55.39) min vs. (275.65±52.23) min ( t=6.31, P<0.001), sleep efficiency improved to (70.96±12.33%) vs. (57.43±10.98%) ( t=11.01, P<0.001) and (62.37±11.28%) vs. (56.78±10.72%) ( t=4.82, P<0.001), while the rTMS group showed greater improvement ( t=4.46, 4.88; P<0.001). Compared to before treatment, left motor thresholds decreased to (55.65±2.48)% vs. (64.37±3.12)% and (61.76±3.17)% vs. (65.12±3.45)% post-treatment ( t=29.54, 9.63; P<0.001), with significant intergroup differences ( t=14.40, P<0.001). Right motor thresholds decreased to (56.28±3.45)% vs. (67.42±3.61)% and (60.89±3.39)% vs. (66.62±3.54)% ( t=29.94, 15.69; P<0.001), with intergroup differences ( t=9.04, P<0.01). Compared to before treatment, serum S100β levels decreased in both group post-treatment (23.65±3.23) ng/L vs. (65.37±7.89) ng/L and (29.76±3.61) ng/L vs. (63.48±7.34) ng/L ( t=71.19, 58.43; P<0.001), with lower levels in the rTMS group ( t=11.97, P<0.001). Compared to before treatment, BDNF increased to (554.48±69.78) ng/L vs. (502.82±64.11) ng/L and (524.90±67.66) ng/L vs. (505.12±64.45) ng/L post-treatment ( t=7.32, 2.84; P=0.001, 0.030), with higher levels in the rTMS group ( t=2.89, P=0.004). Adverse reaction rates were 4.44% (4/90) and 3.33% (3/90), respectively ( χ2=0.15, P=0.700). Recurrence rates were 1.18% (1/85) in the rTMS group and 3.90% (3/77) in the medication group ( χ2=0.37, P=0.544). Conclusion:The combination of dexzopiclone and repetitive transcranial magnetic stimulation (rTMS) demonstrates significant advantages and efficacy in treating post-stroke sleep disorders (PSSD). This approach comprehensively improves patients' sleep quality, EEG parameters and neuroelectrophysiological indicators while enhancing the regulatory effects of brain-derived neurotrophic factor (BDNF). Additionally, the therapy exhibits a favorable safety profile and prognosis.

Objective:To discuss the effect of asiatic acid(AA)on the inflammation and oxidative stress damage induced by lipopolysaccharide(LPS)in the primary cultured hippocampus neurons,and to clarify its mechanism.Methods:The primary cultured rat hippocampus neurons(cell purity identified by immunofluorescence staining)were divided into control group,LPS(10 mg·L-1)group,and LPS+AA group(10 mg·L-1 LPS+10,20,and 40 μmol·L-1 AA),AA group(20 μmol·L-1 AA),ML385 group[10 μmol·L-1 nuclear factor erythroid 2-related factor(Nrf2)inhibitor],and LPS+ML385+AA group(10mg·L-1 LPS+10 μmol·L-1 ML385+20 μmol·L-1 AA).After drug treatment,methylthiazolyldiphenyl-tetrazolium bromide(MTT)method was used to detect the survival rates of the hippocampus neurons in various groups;lactate dehydrogenase(LDH)kit was used to detect the LDH leakage rates of the hippocampus neurons in various groups;enzyme linked immunosorbent assay(ELISA)kit was used to detect the expression levels of inflammatory factors[interleukin(IL)-1β and tumor necrosis factor(TNF)-α]and the activities of superoxide dismutase(SOD)and malondialdehyde(MDA)levels in the hippocampus neurons in various groups;Griess method was used to detect the nitric oxide(NO)levels in supernatant of the hippocampus neurons in various groups;immunofluorescence staining was used to detect the expressions of Nrf2 and heme oxygenase-1(HO-1)proteins in the hippocampus neurons in various groups;Western blotting method was used to detect the expression levels of Nrf2,HO-1,nuclear factor-kappa B(NF-κB),and B-cell lymphoma 2(Bcl-2)proteins in the hippocampus neurons in various groups.Results:Compared with control group,the survival rate of the hippocampus neurons,SOD activity,and Bcl-2 expression level in the cells in LPS group were significantly decreased(P＜0.01),while the LDH leakage rate,expression levels of IL-1β and TNF-α,MDA level,and NO level,as well as the expression level of NF-κB protein,were significantly increased(P＜0.01);the fluorescence intensities and expression levels of Nrf2 and HO-1 proteins in hippocampus neurons were significantly decreased(P＜0.01).Compared with LPS group,the survival rates of hippocampus neurons,SOD activities,and expression levels of Bcl-2 in the cells in LPS+10 μmol·L-1 AA group and 20 μmol·L-1 AA group were significantly increased(P＜0.01),while the LDH leakage rates,expression levels of IL-1β and TNF-α,MDA levels,and NO levels,as well as expression levels of NF-κB protein,were significantly decreased(P＜0.05 or P＜0.01),and the fluorescence intensities and protein expression levels of Nrf2 and HO-1 in the cells were significantly increased(P＜0.01).Compared with LPS+20 μmol·L-1 AA group,the fluorescence intensities of Nrf2 and HO-1 in the cells in LPS+ML385+AA group were significantly decreased(P＜0.01),and the expression levels of Nrf2 protein in the nucleus and cytoplasm,the expression levels of HO-1 and Bcl-2 proteins in the cells were significantly decreased(P＜0.01),while the expression level of NF-κB protein was significantly increased(P＜0.01).Conclusion:AA can improve LPS-induced inflammation and oxidative stress damage in the primary cultured rat hippocampus neurons,and its mechanism may be related to the activation of the Nrf2/HO-1 signaling pathway.

Although in the treatment of extracranial vascular malformations the absolute ethanol used as an embolization agent has several advantages(such as low cost,reliable efficacy,no impact on subsequent treatments,etc.)and has already achieved significant progress in clinical practice,it is still regarded as a highly-selective liquid embolization agent in the sclerotherapy or embolization treatment of brain arteriovenous malformation(bAVM).At present,the indications of sclerotherapy and embolization therapy by using absolute ethanol include small AVM(＜3 cm)located at brain cortex or at non-eloguent area,and relatively low-flow AVM,in such case,the absolute ethanol acts as an effective supplement to other liquid embolization agents.Further studies are needed so as to improve the radiographic visualization and viscosity of absolute ethanol,to make the injection process more controlled,and to alleviate the edema caused by neurotoxicity and inflammation.

Objective:To study the effect of anti-melanoma differentiation-related gene 5(MDA5) antibody positive dermatomyositis on the heart of patients.Methods:A total of 71 patients with dermatomyositis diagnosed in Shandong Provincial Hospital Affiliated to Shandong First Medical University from January 1, 2014 to December 31, 2019 were enrolled as the sample group, including anti-MDA5 (+) group( n=28); anti-MDA5(-) groups( n=43). Electrocardiogram and echocardiography were performed in the sample group and the control group. The electrocardiogram, echocardiography and other relevant clinical data of the anti-MDA5 (+) group, anti-MDA5 (-) group and the healthy control group were retrospectively analyzed. The logistic regression analysis model was used to analyze the related factors influencing cardiac involvement in anti-MDA5 (+) patients. Results:In the anti-MDA5 (+) group, more than half of the patients showed elevated levels of lactate dehydrogenase (21/28, 75%) and α-hydroxybutyrate dehydrogenase (16/28, 57%), and 11%(3/28) showed elevated levels of creatine kinase isoenzyme and myoglobin. Compared with the anti-MDA5 (-) group, the white blood cell count in the blood routine of the anti-MDA5 (+) group [5.2 (4.0, 6.5) ×10 9/L vs. 7.8 (5.6, 10.6)×10 9/L, Z=-3.447, P=0.001], creatine kinase [62.5 (29.3, 108.3) U/L vs. 481.0 (179.0, 2 738.0) U/L, Z=-5.895, P<0.001], lactate dehydrogenase [313.0 (239.0, 362.0) U/L vs. 448.0 (291.0, 542.0) U/L, Z=-3.236, P<0.001], creatine kinase isoenzyme [1.9 (1.1, 3.9)ng/ml vs. 17.7 (4.0, 67.2) ng/ml, Z=-4.724, P<0.001], myoglobin [28.2 (20.0, 43.0) ng/ml vs. 307.4 (48.1, 612.2) ng/ml, Z=-4.800, P<0.001]. Electrocardiogram analysis showed that QRS axis [33.5±265.9 vs. 46.9±22.4, t=-2.900, P=0.004], SV1 amplitude [0.7 (0.4, 0.9) vs. 0.9 (0.7, 1.0), Z=-2.148, P=0.023] in anti-MDA5 antibody (+) group in anti-MDA5 antibody (+) group were lower than anti-MDA5 antibody (-) group. QRS duration [84.0 (78.0, 96.5) vs.92.0 (87.8, 100.5), Z=-2.900, P=0.004], QRS axis [33.5±265.9 vs. 46.9±20.4, Z=-2.32, P=0.023] in the anti-MDA5 antibody (+) group were lower than those in healthy control group. Echocardiographic analysis showed that the E peak of anti-MDA5 (+) group [63.0 (52.5, 69.5)] was significantly lower than that of anti-MDA5 (-) group [85.0 (68.0, 108.0), Z=-4.926, P<0.001)]and healthy control group [67.0 (62.8, 80.3), Z=-2.897, P=0.004]. The peak A of anti-MDA5 (+) group [65.5 (56.5, 80.0)] was significantly lower than that of anti-MDA5 (-) group [76.0 (65.0, 90.0), Z=-2.631, P=0.011], but higher than that of healthy control group [55.0(51.0, 66.5), Z=-4.550, P<0.001]. There was no significant difference in echocardiographic findi-ngs among the other groups. All patients with anti-MDA5 (+) dermatomyositis had interstitial lung disease (28/28, 100%). Patients with MDA5 antibody (+++) are more likely to have cardiac involvement than patients with MDA5 antibody (++). Conclusion:The results of relevant examinations in anti-MDA5-DM patients suggest that there is damage to myocardial cells and cardiac function.

Objective To explore the changes in neural activity in patients with type 2 diabetes mellitus(T2DM)and their corre-lation with executive function,and to analyze the neural mechanisms underlying the decline in executive function in T2DM patients.Methods Thirty-one T2DM patients(T2DM group)and thirty-two healthy controls(HC)(HC group)matched for body mass index(BMI)underwent resting-state functional magnetic resonance imaging(rs-fMRI)scans and N-back task tests were included.Differ-ences in the amplitude of low-frequency fluctuation(ALFF),regional homogeneity(ReHo),and seed-based functional connectivity(FC)between the two groups were compared,and partial correlation analyses were performed between the difference results and N-back task performance.Results The T2DM group showed prolonged reaction time(RT)in the 1-back and 2-back tasks.T2DM patients exhibited increased ALFF in the bilateral caudate nucleus,left medial superior frontal gyrus,and right postcentral gyrus,as well as elevated ReHo in the right putamen.FC analysis revealed significant alterations in FC between the caudate nucleus,putamen,and multiple brain regions in T2DM patients,with some of these FC changes significantly correlated with RT and accuracy(ACC)in the N-back task.Conclusion The decline in executive function in T2DM patients may be associated with abnormal neural activity in brain regions such as the striatum,salience network,and frontoparietal control network.FC further decreases under increased cognitive load.These findings provide evidence for the study of the neural mechanisms of executive function impairment in T2DM patients.

Objective To investigate the effect and mechanism of remimazolam on circulatory function in septic shock rats.Methods Seventy-two SPF grade rats were randomly divided into the control group,the model group,the dexamethasone group,the low and high dose remimazolam groups and the high-dose remimazolam+Nrf2 inhibitor(ML385)group,with 12 rats in each group.The septic shock rat model was established by intravenous infusion of 10 mg/kg lipopolysaccharide(LPS).After 6 hours of modeling,the mean arterial pressure(MAP)and heart rate(HR)of rats were measured.Enzyme linked immunosorbent assay(ELISA)method was applied to measure serum levels of lactic acid(Lac),tumor necrosis factor-α(TNF-α),interleukin(IL)-1β,IL-6,nitric oxide(NO),and endothelin-1(ET-1).Hematoxylin-eosin(HE)staining was applied to observe morphological changes in vascular tissue.TUNEL staining was applied to observe the apoptosis of vascular endothelial cells.DHE fluorescent probe was used to detect the level of ROS in vascular tissue.The colorimetric method was applied to detect the contents of MDA and the activity of SOD in vascular tissue.Western blot assay was applied to detect the protein expression of nuclear factor E2-related factor 2(Nrf2)and glutathione peroxidase 4(GPX4)in vascular tissue.Results Compared with the control group,MAP,SOD activity in vascular tissue,Nrf2 and GPX4 protein levels were lower in the model group,while HR,serum Lac,NO,ET-1,TNF-α,IL-1β,IL-6 levels,endothelial cell apoptosis rate,ROS level in vascular tissue and MDA content were higher(P＜0.05).Compared with the model group,MAP,SOD activity in vascular tissue,Nrf2 and GPX4 protein levels were higher in the dexamethasone group and in the low and high dose remimazolam groups,while HR,serum Lac,NO,ET-1,TNF-α,IL-1β,IL-6 levels,endothelial cell apoptosis rate,ROS level in vascular tissue and MDA content were lower(P＜0.05).Nrf2 inhibitor ML385 greatly reduced the protective effect of remimazolam on septic shock rats(P＜0.05).Conclusion Remimazolam may improve circulatory function in septic shock rats by activating the Nrf2/GPX4 pathway,inhibiting inflammatory response and oxidative stress,reducing endothelial cell damage.

Objective To investigate the effect and mechanism of remimazolam on circulatory function in septic shock rats.Methods Seventy-two SPF grade rats were randomly divided into the control group,the model group,the dexamethasone group,the low and high dose remimazolam groups and the high-dose remimazolam+Nrf2 inhibitor(ML385)group,with 12 rats in each group.The septic shock rat model was established by intravenous infusion of 10 mg/kg lipopolysaccharide(LPS).After 6 hours of modeling,the mean arterial pressure(MAP)and heart rate(HR)of rats were measured.Enzyme linked immunosorbent assay(ELISA)method was applied to measure serum levels of lactic acid(Lac),tumor necrosis factor-α(TNF-α),interleukin(IL)-1β,IL-6,nitric oxide(NO),and endothelin-1(ET-1).Hematoxylin-eosin(HE)staining was applied to observe morphological changes in vascular tissue.TUNEL staining was applied to observe the apoptosis of vascular endothelial cells.DHE fluorescent probe was used to detect the level of ROS in vascular tissue.The colorimetric method was applied to detect the contents of MDA and the activity of SOD in vascular tissue.Western blot assay was applied to detect the protein expression of nuclear factor E2-related factor 2(Nrf2)and glutathione peroxidase 4(GPX4)in vascular tissue.Results Compared with the control group,MAP,SOD activity in vascular tissue,Nrf2 and GPX4 protein levels were lower in the model group,while HR,serum Lac,NO,ET-1,TNF-α,IL-1β,IL-6 levels,endothelial cell apoptosis rate,ROS level in vascular tissue and MDA content were higher(P＜0.05).Compared with the model group,MAP,SOD activity in vascular tissue,Nrf2 and GPX4 protein levels were higher in the dexamethasone group and in the low and high dose remimazolam groups,while HR,serum Lac,NO,ET-1,TNF-α,IL-1β,IL-6 levels,endothelial cell apoptosis rate,ROS level in vascular tissue and MDA content were lower(P＜0.05).Nrf2 inhibitor ML385 greatly reduced the protective effect of remimazolam on septic shock rats(P＜0.05).Conclusion Remimazolam may improve circulatory function in septic shock rats by activating the Nrf2/GPX4 pathway,inhibiting inflammatory response and oxidative stress,reducing endothelial cell damage.

Objective To explore the changes in neural activity in patients with type 2 diabetes mellitus(T2DM)and their corre-lation with executive function,and to analyze the neural mechanisms underlying the decline in executive function in T2DM patients.Methods Thirty-one T2DM patients(T2DM group)and thirty-two healthy controls(HC)(HC group)matched for body mass index(BMI)underwent resting-state functional magnetic resonance imaging(rs-fMRI)scans and N-back task tests were included.Differ-ences in the amplitude of low-frequency fluctuation(ALFF),regional homogeneity(ReHo),and seed-based functional connectivity(FC)between the two groups were compared,and partial correlation analyses were performed between the difference results and N-back task performance.Results The T2DM group showed prolonged reaction time(RT)in the 1-back and 2-back tasks.T2DM patients exhibited increased ALFF in the bilateral caudate nucleus,left medial superior frontal gyrus,and right postcentral gyrus,as well as elevated ReHo in the right putamen.FC analysis revealed significant alterations in FC between the caudate nucleus,putamen,and multiple brain regions in T2DM patients,with some of these FC changes significantly correlated with RT and accuracy(ACC)in the N-back task.Conclusion The decline in executive function in T2DM patients may be associated with abnormal neural activity in brain regions such as the striatum,salience network,and frontoparietal control network.FC further decreases under increased cognitive load.These findings provide evidence for the study of the neural mechanisms of executive function impairment in T2DM patients.

Objective:To evaluate the efficacy of dexzopiclone combined with repetitive transcranial magnetic stimulation (rTMS) for post-stroke sleep disorders (PSSD) and its effects on sleep electroencephalography and neuroelectrophysiological parameters.Methods:180 PSSD patients admitted to Yulin First Hospital (December 2019-December 2020) were randomized into medication group ( n=90, dexzopiclone) and rTMS group ( n=90, dexzopiclone+rTMS). Outcomes included clinical efficacy, sleep quality [Pittsburgh Sleep Quality Index (PSQI), Self-Rating Scale for Sleep (SRSS)], electroencephalogram parameters [sleep latency (SL), total sleep time (TST), sleep efficiency], neuroelectrophysiological indices [bilateral motor thresholds], biochemical markers [S100β protein, brain-derived neurotrophic factor (BDNF)], adverse reactions, and 1-year recurrence rate. Results:After treatment, the rTMS group had a significantly higher efficacy (92.22%, 83/90) compared to the medication group (81.11%, 73/90) ( χ2=4.81, P=0.028). Compared to post-treatment, PSQI decreased to [7.47 (6.63,8.69) points vs. 13.56 (3.15,19.51) points] in the rTMS group and [9.56 (8.59,11.11) points vs. 14.01 (2.58,20.55) points] in the medication group ( U=8.82, 8.38; both P<0.001). SRSS scores decreased to [(15.23±2.88) points vs. (28.81±4.99) points) ( t=32.74, P<0.001) and (19.54±3.59) points vs. (28.15±4.71) points) ( t=19.68, P<0.001)], respectively. Compared to before treatment, the rTMS group had lower scores than the medication group ( U=7.80, t=8.88; P<0.01). SL reduced to (27.65±5.12) min vs. (44.92±8.21) min ( t=24.58, P<0.001) in rTMS group and (38.78±6.34) min vs. (45.23±8.56) min ( t=8.24, P<0.001) in medication groups. TST increased to (348.50±56.27) min vs. (299.21±52.14) min ( t=8.63, P<0.001) and (311.42±55.39) min vs. (275.65±52.23) min ( t=6.31, P<0.001), sleep efficiency improved to (70.96±12.33%) vs. (57.43±10.98%) ( t=11.01, P<0.001) and (62.37±11.28%) vs. (56.78±10.72%) ( t=4.82, P<0.001), while the rTMS group showed greater improvement ( t=4.46, 4.88; P<0.001). Compared to before treatment, left motor thresholds decreased to (55.65±2.48)% vs. (64.37±3.12)% and (61.76±3.17)% vs. (65.12±3.45)% post-treatment ( t=29.54, 9.63; P<0.001), with significant intergroup differences ( t=14.40, P<0.001). Right motor thresholds decreased to (56.28±3.45)% vs. (67.42±3.61)% and (60.89±3.39)% vs. (66.62±3.54)% ( t=29.94, 15.69; P<0.001), with intergroup differences ( t=9.04, P<0.01). Compared to before treatment, serum S100β levels decreased in both group post-treatment (23.65±3.23) ng/L vs. (65.37±7.89) ng/L and (29.76±3.61) ng/L vs. (63.48±7.34) ng/L ( t=71.19, 58.43; P<0.001), with lower levels in the rTMS group ( t=11.97, P<0.001). Compared to before treatment, BDNF increased to (554.48±69.78) ng/L vs. (502.82±64.11) ng/L and (524.90±67.66) ng/L vs. (505.12±64.45) ng/L post-treatment ( t=7.32, 2.84; P=0.001, 0.030), with higher levels in the rTMS group ( t=2.89, P=0.004). Adverse reaction rates were 4.44% (4/90) and 3.33% (3/90), respectively ( χ2=0.15, P=0.700). Recurrence rates were 1.18% (1/85) in the rTMS group and 3.90% (3/77) in the medication group ( χ2=0.37, P=0.544). Conclusion:The combination of dexzopiclone and repetitive transcranial magnetic stimulation (rTMS) demonstrates significant advantages and efficacy in treating post-stroke sleep disorders (PSSD). This approach comprehensively improves patients' sleep quality, EEG parameters and neuroelectrophysiological indicators while enhancing the regulatory effects of brain-derived neurotrophic factor (BDNF). Additionally, the therapy exhibits a favorable safety profile and prognosis.

Objective:To study the effect of anti-melanoma differentiation-related gene 5(MDA5) antibody positive dermatomyositis on the heart of patients.Methods:A total of 71 patients with dermatomyositis diagnosed in Shandong Provincial Hospital Affiliated to Shandong First Medical University from January 1, 2014 to December 31, 2019 were enrolled as the sample group, including anti-MDA5 (+) group( n=28); anti-MDA5(-) groups( n=43). Electrocardiogram and echocardiography were performed in the sample group and the control group. The electrocardiogram, echocardiography and other relevant clinical data of the anti-MDA5 (+) group, anti-MDA5 (-) group and the healthy control group were retrospectively analyzed. The logistic regression analysis model was used to analyze the related factors influencing cardiac involvement in anti-MDA5 (+) patients. Results:In the anti-MDA5 (+) group, more than half of the patients showed elevated levels of lactate dehydrogenase (21/28, 75%) and α-hydroxybutyrate dehydrogenase (16/28, 57%), and 11%(3/28) showed elevated levels of creatine kinase isoenzyme and myoglobin. Compared with the anti-MDA5 (-) group, the white blood cell count in the blood routine of the anti-MDA5 (+) group [5.2 (4.0, 6.5) ×10 9/L vs. 7.8 (5.6, 10.6)×10 9/L, Z=-3.447, P=0.001], creatine kinase [62.5 (29.3, 108.3) U/L vs. 481.0 (179.0, 2 738.0) U/L, Z=-5.895, P<0.001], lactate dehydrogenase [313.0 (239.0, 362.0) U/L vs. 448.0 (291.0, 542.0) U/L, Z=-3.236, P<0.001], creatine kinase isoenzyme [1.9 (1.1, 3.9)ng/ml vs. 17.7 (4.0, 67.2) ng/ml, Z=-4.724, P<0.001], myoglobin [28.2 (20.0, 43.0) ng/ml vs. 307.4 (48.1, 612.2) ng/ml, Z=-4.800, P<0.001]. Electrocardiogram analysis showed that QRS axis [33.5±265.9 vs. 46.9±22.4, t=-2.900, P=0.004], SV1 amplitude [0.7 (0.4, 0.9) vs. 0.9 (0.7, 1.0), Z=-2.148, P=0.023] in anti-MDA5 antibody (+) group in anti-MDA5 antibody (+) group were lower than anti-MDA5 antibody (-) group. QRS duration [84.0 (78.0, 96.5) vs.92.0 (87.8, 100.5), Z=-2.900, P=0.004], QRS axis [33.5±265.9 vs. 46.9±20.4, Z=-2.32, P=0.023] in the anti-MDA5 antibody (+) group were lower than those in healthy control group. Echocardiographic analysis showed that the E peak of anti-MDA5 (+) group [63.0 (52.5, 69.5)] was significantly lower than that of anti-MDA5 (-) group [85.0 (68.0, 108.0), Z=-4.926, P<0.001)]and healthy control group [67.0 (62.8, 80.3), Z=-2.897, P=0.004]. The peak A of anti-MDA5 (+) group [65.5 (56.5, 80.0)] was significantly lower than that of anti-MDA5 (-) group [76.0 (65.0, 90.0), Z=-2.631, P=0.011], but higher than that of healthy control group [55.0(51.0, 66.5), Z=-4.550, P<0.001]. There was no significant difference in echocardiographic findi-ngs among the other groups. All patients with anti-MDA5 (+) dermatomyositis had interstitial lung disease (28/28, 100%). Patients with MDA5 antibody (+++) are more likely to have cardiac involvement than patients with MDA5 antibody (++). Conclusion:The results of relevant examinations in anti-MDA5-DM patients suggest that there is damage to myocardial cells and cardiac function.